Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 22053102.
- Also identified by DOI 10.1136/bjophthalmol-2011-300183.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chronic central serous retinopathy (CSR) is characterised by frequent exacerbations and a poor visual prognosis. Very few therapies exist for chronic CSR, and the existing therapies are often ineffective. Thus, novel therapies to combat this frustrating disorder are needed. Presented here is a case detailing a patient with chronic CSR with persistent subfoveal fluid of 2 years' duration that completely resolved with 1 month of oral rifampin therapy. As a cytochrome P450, 3A4 inducer, rifampin is thought to favourably alter the metabolism of endogenous steroids, thereby leading to an improvement in CSR manifestations.
Medical subject headings
- Central Serous Chorioretinopathy
- Nucleic Acid Synthesis Inhibitors
- Postoperative Complications
- Rifampin